Renal Protective Effect of Everolimus in Liver Transplantation: A Prospective Randomized Open-Label Trial.

Transplant Direct · 2021 · PMC8191692 · PMID 34124345

Europe PMC DOI

hedged sentences

0.0830

closest p · 1.7× alpha

0.0830

boldest claim

The sentences

did not reach statistical significanceP = 0.083so close (0.05 < p ≤ 0.1)

There was a higher incidence of cytomegalovirus infections in the SOC arm (SOC n = 6; EV n = 2), although this did not reach statistical significance ( P = 0.083).

also in 111,027 other papers

a strong trendno p-value reported

13 The iothalamate clearance in the EVR arm showed a strong trend toward renal function improvement but did not reach significance by 24 months ( P = 0.099), which may have been due to lower subject numbers by month 24 (n = 8).

also in 5,725 other papers

a nonsignificant trendno p-value reported

This resulted in up to 47.7% of EVR arm subjects receiving tacrolimus at some time point during the 6- to 24-month follow-up, and in the CERTITUDE study, the observed eGFR was only significantly higher at 3–12 months in the EVR group, with a nonsignificant trend to higher GFR thereafter.

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.